C-Type Natriuretic Peptide (32-53) (human, porcine, rat) acetate salt structure
|
Common Name | C-Type Natriuretic Peptide (32-53) (human, porcine, rat) acetate salt | ||
---|---|---|---|---|
CAS Number | 127869-51-6 | Molecular Weight | 2197.60000 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C93H157N27O28S3 | Melting Point | N/A | |
MSDS | Chinese USA | Flash Point | N/A |
Use of C-Type Natriuretic Peptide (32-53) (human, porcine, rat) acetate saltC-Type Natriuretic Peptide (CNP) (1-22), human is the 1-22 fragment of C-Type Natriuretic Peptide. C-type natriuretic peptide is natriuretic peptide family peptide that is involved in the maintenance of electrolyte-fluid balance and vascular tone. |
Name | Natriuretic peptide, C-type |
---|---|
Synonym | More Synonyms |
Description | C-Type Natriuretic Peptide (CNP) (1-22), human is the 1-22 fragment of C-Type Natriuretic Peptide. C-type natriuretic peptide is natriuretic peptide family peptide that is involved in the maintenance of electrolyte-fluid balance and vascular tone. |
---|---|
Related Catalog | |
In Vitro | C-Type Natriuretic Peptide (CNP) has been shown to be present in the central nervous system of mammals and to participate in the regulation of the homeostasis of the fluid, electrolytic balance and blood pressure, learning and memory[1]. |
In Vivo | I.c.v. administration of C-Type Natriuretic Peptide (CNP) (1-22) in a dose of 2 nM induces an increase in the severity of picrotoxin-kindled convulsions 24 and 48 hrs after application of the peptide[1]. |
Animal Admin | Rats[1] Rats are preliminarily kindled with picrotoxin and convulsion is monitored. Rats then receive I.c.v. administration of C-Type Natriuretic Peptide (CNP) (1-22) (0.2, 1 or 2 nM in 2 mcl of 0.9% NaCI) under conditions of free behavior. Control animals receive an equal volume of saline. Within 10 min after the injections of the peptides, picrotoxin (1.5 mg/kg) is administered i.p. and the convulsion severity is evaluated as mentioned above[1]. |
References |
Molecular Formula | C93H157N27O28S3 |
---|---|
Molecular Weight | 2197.60000 |
Exact Mass | 2196.09000 |
PSA | 962.25000 |
LogP | 0.46880 |
Storage condition | -20°C |
Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
---|---|
Hazard Codes | Xi |
RIDADR | NONH for all modes of transport |
WGK Germany | 3.0 |
Minimizing the non-specific binding of nanoparticles to the brain enables active targeting of Fn14-positive glioblastoma cells.
Biomaterials 42 , 42-51, (2014) A major limitation in the treatment of glioblastoma (GBM), the most common and deadly primary brain cancer, is delivery of therapeutics to invading tumor cells outside of the area that is safe for sur... |
|
Development of anti-HER2 fragment antibody conjugated to iron oxide nanoparticles for in vivo HER2-targeted photoacoustic tumor imaging.
Nanomedicine: Nanotechnology, Biology, and Medicine 11 , 2051-60, (2015) Photoacoustic (PA) imaging is a promising imaging modality that provides biomedical information with high sensitivity and resolution. Iron oxide nanoparticles (IONPs) have been regarded as remarkable ... |
|
C-type natriuretic peptide attenuates lipopolysaccharide-induced acute lung injury in mice.
J. Surg. Res. 194(2) , 631-7, (2015) C-type natriuretic peptide (CNP), secreted by vascular endothelial cells, belongs to a family of peptides that includes atrial and brain natriuretic peptides. CNP exhibits many vasoprotective effects ... |
Dihydrexidine hydrochloride |
MFCD00080348 |
C-Type natriuretic peptide |
GLY-LEU-SER-LYS-GLY-CYS-PHE-GLY-LEU-LYS-LEU-ASP-ARG-ILE-GLY-SER-MET-SER-GLY-LEU-GLY-CYS(DISULFIDE BRIDGE:CYS6-CYS22) |
NATRIURETIC PEPTIDE,C-TYPE |
CNP |
GLY-LEU-SER-LYS-GLY-CYS-PHE-GLY-LEU-LYS-LEU-ASP-ARG-ILE-GLY-SER-MET-SER-GLY-LEU-GLY-CYS: GLSKGCFGLKLDRIGSMSGLGCDISULFIDE BRIDGE CYS6-CYS22 |
C-Type Natriuretic Peptide (CNP) (1-22), human |